Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Up 47.6% in January

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 21,700 shares, an increase of 47.6% from the January 15th total of 14,700 shares. Based on an average trading volume of 20,400 shares, the days-to-cover ratio is presently 1.1 days.

Emmaus Life Sciences Stock Performance

Shares of OTCMKTS EMMA opened at $0.04 on Friday. Emmaus Life Sciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.13. The stock has a market cap of $2.85 million, a price-to-earnings ratio of -0.50 and a beta of 6.64. The firm’s 50-day simple moving average is $0.02 and its 200 day simple moving average is $0.02.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.